Erythropoietin: Physiology and clinical applications

Research output: Contribution to journalArticle

Abstract

Recombinant human erythropoietin (rhEpo) has come of age. Clinical trials have substantiated that the hormone can alleviate transfusion requirements, correct anemia and improve the quality of life in patients with end‐stage renal disease. Epo is also effective in correcting anemia in patients with rheumatoid arthritis, in AIDS patients taking zidovudine and in patients with various malignancies both off and on chemotherapy. Autologous blood donors are able to donate more blood with less of a deficit in red cell mass when receiving Epo, and preliminary studies suggest that Epo may have a role in correcting the anemia of prematurity. The most cost effective and promising role for the hormone, apart from its use in patients with end‐stage kidney disease, is likely to be in the prevention of the need for homologous blood transfusion in a variety of clinical situations such as the perisurgical period, the anemia associated with prematurity, the period following bone marrow transplantation, and in anticipation of various forms of chemotherapy or retroviral therapy.

Original languageEnglish (US)
Pages (from-to)105-120
Number of pages16
JournalInternational Journal of Cell Cloning
Volume9
Issue number1 S
DOIs
StatePublished - 1991

Fingerprint

Erythropoietin
Anemia
Hormones
Erythrocyte Volume
Drug Therapy
Zidovudine
Kidney Diseases
Blood Donors
Bone Marrow Transplantation
Blood Transfusion
Rheumatoid Arthritis
Acquired Immunodeficiency Syndrome
Quality of Life
Clinical Trials
Kidney
Costs and Cost Analysis
Neoplasms
Therapeutics

Keywords

  • Erythropoietin
  • Physiology
  • Therapy

ASJC Scopus subject areas

  • Cell Biology

Cite this

Erythropoietin : Physiology and clinical applications. / Spivak, Jerry L.

In: International Journal of Cell Cloning, Vol. 9, No. 1 S, 1991, p. 105-120.

Research output: Contribution to journalArticle

@article{8fee352372a94ad0b386c487ee546c94,
title = "Erythropoietin: Physiology and clinical applications",
abstract = "Recombinant human erythropoietin (rhEpo) has come of age. Clinical trials have substantiated that the hormone can alleviate transfusion requirements, correct anemia and improve the quality of life in patients with end‐stage renal disease. Epo is also effective in correcting anemia in patients with rheumatoid arthritis, in AIDS patients taking zidovudine and in patients with various malignancies both off and on chemotherapy. Autologous blood donors are able to donate more blood with less of a deficit in red cell mass when receiving Epo, and preliminary studies suggest that Epo may have a role in correcting the anemia of prematurity. The most cost effective and promising role for the hormone, apart from its use in patients with end‐stage kidney disease, is likely to be in the prevention of the need for homologous blood transfusion in a variety of clinical situations such as the perisurgical period, the anemia associated with prematurity, the period following bone marrow transplantation, and in anticipation of various forms of chemotherapy or retroviral therapy.",
keywords = "Erythropoietin, Physiology, Therapy",
author = "Spivak, {Jerry L}",
year = "1991",
doi = "10.1002/stem.5530090713",
language = "English (US)",
volume = "9",
pages = "105--120",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "1 S",

}

TY - JOUR

T1 - Erythropoietin

T2 - Physiology and clinical applications

AU - Spivak, Jerry L

PY - 1991

Y1 - 1991

N2 - Recombinant human erythropoietin (rhEpo) has come of age. Clinical trials have substantiated that the hormone can alleviate transfusion requirements, correct anemia and improve the quality of life in patients with end‐stage renal disease. Epo is also effective in correcting anemia in patients with rheumatoid arthritis, in AIDS patients taking zidovudine and in patients with various malignancies both off and on chemotherapy. Autologous blood donors are able to donate more blood with less of a deficit in red cell mass when receiving Epo, and preliminary studies suggest that Epo may have a role in correcting the anemia of prematurity. The most cost effective and promising role for the hormone, apart from its use in patients with end‐stage kidney disease, is likely to be in the prevention of the need for homologous blood transfusion in a variety of clinical situations such as the perisurgical period, the anemia associated with prematurity, the period following bone marrow transplantation, and in anticipation of various forms of chemotherapy or retroviral therapy.

AB - Recombinant human erythropoietin (rhEpo) has come of age. Clinical trials have substantiated that the hormone can alleviate transfusion requirements, correct anemia and improve the quality of life in patients with end‐stage renal disease. Epo is also effective in correcting anemia in patients with rheumatoid arthritis, in AIDS patients taking zidovudine and in patients with various malignancies both off and on chemotherapy. Autologous blood donors are able to donate more blood with less of a deficit in red cell mass when receiving Epo, and preliminary studies suggest that Epo may have a role in correcting the anemia of prematurity. The most cost effective and promising role for the hormone, apart from its use in patients with end‐stage kidney disease, is likely to be in the prevention of the need for homologous blood transfusion in a variety of clinical situations such as the perisurgical period, the anemia associated with prematurity, the period following bone marrow transplantation, and in anticipation of various forms of chemotherapy or retroviral therapy.

KW - Erythropoietin

KW - Physiology

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=84995106415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84995106415&partnerID=8YFLogxK

U2 - 10.1002/stem.5530090713

DO - 10.1002/stem.5530090713

M3 - Article

AN - SCOPUS:84995106415

VL - 9

SP - 105

EP - 120

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 1 S

ER -